User menu

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

Bibliographic reference Ivanoiu, Adrian ; Pariente, Jérémie ; Booth, Kevin ; Lobello, Kasia ; Luscan, Gerald ; et. al. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies. In: Alzheimer's Research & Therapy, Vol. 8, no.1 (2016)
Permanent URL http://hdl.handle.net/2078.1/175250
  1. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18. Erratum: Nat Rev Neurol. 2013. doi: 10.1038/nmeurol.2013.32 .
  2. Madeo J, Frieri M. Alzheimer’s disease and immunotherapy. Aging Dis. 2013;4:210–20.
  3. Singh S, Kushwah AS, Singh R, Farswan M, Kaur R. Current therapeutic strategy in Alzheimer’s disease. Eur Rev Med Pharmacol Sci. 2012;16:1651–64.
  4. Lemere Cynthia A, Immunotherapy for Alzheimer’s disease: hoops and hurdles, 10.1186/1750-1326-8-36
  5. Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. 2013. http://www.alz.org/downloads/facts_figures_2013.pdf . Accessed 8 Dec 2015.
  6. Tayeb Haythum O, Murray Evan D, Price Bruce H, Tarazi Frank I, Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?, 10.1517/14712598.2013.789856
  7. Salloway Stephen, Sperling Reisa, Fox Nick C., Blennow Kaj, Klunk William, Raskind Murray, Sabbagh Marwan, Honig Lawrence S., Porsteinsson Anton P., Ferris Steven, Reichert Marcel, Ketter Nzeera, Nejadnik Bijan, Guenzler Volkmar, Miloslavsky Maja, Wang Daniel, Lu Yuan, Lull Julia, Tudor Iulia Cristina, Liu Enchi, Grundman Michael, Yuen Eric, Black Ronald, Brashear H. Robert, Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease, 10.1056/nejmoa1304839
  8. Salloway S., Sperling R., Gilman S., Fox N. C., Blennow K., Raskind M., Sabbagh M., Honig L. S., Doody R., van Dyck C. H., Mulnard R., Barakos J., Gregg K. M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M., , A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, 10.1212/wnl.0b013e3181c67808
  9. Sperling Reisa A., Jack Clifford R., Black Sandra E., Frosch Matthew P., Greenberg Steven M., Hyman Bradley T., Scheltens Philip, Carrillo Maria C., Thies William, Bednar Martin M., Black Ronald S., Brashear H. Robert, Grundman Michael, Siemers Eric R., Feldman Howard H., Schindler Rachel J., Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup, 10.1016/j.jalz.2011.05.2351
  10. Doody Rachelle S., Thomas Ronald G., Farlow Martin, Iwatsubo Takeshi, Vellas Bruno, Joffe Steven, Kieburtz Karl, Raman Rema, Sun Xiaoying, Aisen Paul S., Siemers Eric, Liu-Seifert Hong, Mohs Richard, Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease, 10.1056/nejmoa1312889
  11. Panza Francesco, Solfrizzi Vincenzo, Imbimbo Bruno P, Giannini Michele, Santamato Andrea, Seripa Davide, Logroscino Giancarlo, Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease, 10.1586/14737175.2014.945522
  12. Blennow Kaj, de Leon Mony J, Zetterberg Henrik, Alzheimer's disease, 10.1016/s0140-6736(06)69113-7
  13. Blennow Kaj, Hampel Harald, Zetterberg Henrik, Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease, 10.1038/npp.2013.154